Manzi et al. Data on anifrolumab from TULIP studies on depression/suicidality. No effect. @RheumNow #EULAR2022 OP0282 https://t.co/5n7HBqzLkX https://t.co/fq4dxskJaA

• EULAR Abstract Archive

#POS0757 #EULAR2022 What is the perception of #lupus patients on #COVID19 recovery? A survey of 202 pts from BILAG-BR (N=20 case+, 3 hospitalised) reported full recovery from covid in only 1/3 of patients. These pts would need extra support @RheumNow https://t.co/SdH223Lfoa

Schett et al. CAR-T in SLE, case series 4 patients. Effective in inducing clinical remission in all 4 refractory patients. Looks like #rheummadness may have been (almost) correct @DavidLeverenz ! @RheumNow #EULAR2022 OP0279 https://t.co/frAU8COFs8

• EULAR Abstract Archive

More data on #iberdomide… from phase 2 study --looks like it helps #SCLE and #CCLE (but not for #ACLE) Dr. V Werth #EULAR2022 @rheumnow https://t.co/FYZlB219lf

Potential new target anti-BDCA2 Ab, #litifilimab targets pDC… impressive phase 2 studies with sig improvement in CLASI-A scores #EULAR2022 @rheumnow https://t.co/hJGx3c3Fbb

#PEARLS by Dr. Werth: 1. anti-malarials only work 50% of time for cutaneous lupus (CLE). 2. AZP is not as effective as MTX or MMF for #CLE 3. Consider RTX refractory #bullous lupus #EULAR2022 @rheumnow https://t.co/6FPJEGWioJ

Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow

#PEARLS by EULAR President Prof Iagnocco: 1. Enthesitis can be present in 25% of #SLE patients 2. Erosions can be common and independent of ACPA/RF status 3. Active myositis is indistinguishable from IIM 4. Don't forget pain osteonecrosis/osteomyelitis #EULAR2022 @rheumnow https://t.co/8uWCw9rEve

Staggering facts by Prof Vital on #SLE and SkM Sx’s: - 50% of first Sx’s is SkM - SkM Sx are in top 3 concerns for pts - 34% pts w/SkM Sx stopped working median 4 yrs - SkM damage clusters with CVD damage #EULAR2022 @rheumnow https://t.co/NXEW3XYCQZ

“#SLEDAI should be scored when there is joint swelling (not just tenderness)—note that only 48% of pts with tenderness will have u/s evidence of inflammation” – Prof E Vital #EULAR2022 @rheumnow https://t.co/hhsZ9wMAWs

Dr. Werth shared her evidence based algorithm for managing cutaneous lupus published here: https://t.co/RytrxLdLHK #EULAR2022 @rheumnow https://t.co/wq28btM24U

• https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41480

OP0283 MMF vs CYP for induction of remission #LupusNephritis. Real world Beijing cohort. n=360 50% Rx naïve. CRR at 1 yr was more common in MMF, esp proliferative LN. GI & infection more common w/CYP. Lower prednisone dose and Urinary protein seen in MMF #EULAR2022 @rheumnow https://t.co/4P43j1rApF

OP0280 WIN-lupus study eval if #SLE LN pts in remission can stop Rx. In pts who continued vs. stopped Rx: renal relapse 12% vs. 27%, p=0.08 and severe SLE flare 12 vs 32%, p=0.03; pts relapsing had inc baseline UPCR/SLEDAI score; +APS; lower lymphs/C3 . #EULAR2022 @rheumnow

Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 https://t.co/yMJcMAFSh6

Promising! Prof Schett presents the 1st 5 #SLE pts who received CAR T cell therapy - all went into sustained remission off of meds: new B cells reconstituted at 100 days but SLE did not. OP0279 #EULAR2022 @rheumnow https://t.co/o3Ehp55C4Q